Sep 04, 2025
BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceVIEW RELEASE
Aug 27, 2025
BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®VIEW RELEASE
Aug 26, 2025
BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025VIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Sep 09, 2025 02:40 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
3.68
CHANGE
-0.55 (-13.02%)
